Altmetric

Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results

Title: Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results
Authors: Pebody, R
Warburton, F
Ellis, J
Andrews, N
Potts, A
Cottrell, S
Johnston, J
Reynolds, A
Gunson, R
Thompson, C
Galiano, M
Robertson, C
Byford, R
Gallagher, N
Sinnathamby, M
Yonova, I
Pathirannehelage, S
Donati, M
Moore, C
De Lusignan, S
McMenamin, J
Zambon, M
Item Type: Journal Article
Abstract: The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season’s adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4% (95% confidence interval (CI): 41.0–61.6) against influenza-confirmed primary care consultation, 54.5% (95% CI: 41.6–64.5) against influenza A(H1N1)pdm09 and 54.2% (95% CI: 33.1–68.6) against influenza B. In 2–17 year-olds, adjusted VE for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any influenza, 81.4% (95% CI: 39.6–94.3) against influenza B and 41.5% (95% CI: −8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.
Issue Date: 22-Sep-2016
Date of Acceptance: 30-Aug-2016
URI: http://hdl.handle.net/10044/1/56850
DOI: https://dx.doi.org/10.2807/1560-7917.ES.2016.21.38.30348
ISSN: 1560-7917
Publisher: European Centre for Disease Prevention and Control
Start Page: 41
End Page: 51
Journal / Book Title: Eurosurveillance
Volume: 21
Issue: 38
Copyright Statement: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. This article is copyright of the authors, 2016.
Keywords: Science & Technology
Life Sciences & Biomedicine
Infectious Diseases
VIRUS
TIME
AGE
STATES
PCR
immunisation
influenza
vaccines
Adolescent
Adult
Aged
Case-Control Studies
Child
Child, Preschool
Disease Outbreaks
Female
Humans
Immunization Programs
Influenza A Virus, H1N1 Subtype
Influenza B virus
Influenza Vaccines
Influenza, Human
Laboratories
Male
Middle Aged
Outcome Assessment (Health Care)
Population Surveillance
Primary Health Care
Reverse Transcriptase Polymerase Chain Reaction
Seasons
United Kingdom
Vaccination
Vaccine Potency
Vaccines, Attenuated
Young Adult
Publication Status: Published
Article Number: 30348
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx